Asthma Flashcards

1
Q

Asthma is defined by the presence of both of the
following:
1
2

A
  • excessive variation in lung function

* respiratory symptoms (

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is meant by excessive variation in lung function

A

(‘variable airflow limitation’ i.e. variation in expiratory
airflow that is greater than that seen in healthy
people)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

In young children in whom lung function testing
is not feasible, including most preschool children,
asthma is defined by the___________

A

presence of variable respiratory symptoms.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

BA

It has an unacceptable mortality rate of
approximately________of the population.

A

5 per 100 000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

BA

It tends to develop between the ages of _______ but can develop at any age

A

2 and 7 years,

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Key test for BA

A

Spirometry is the key investigation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

New aerosols, notably _________
have non-CFC propellants leading to increased
lung deposition and thus requiring overall lower
dosage.

A

hydrofluoroalkanes,

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Pathophysio of BA

  • infiltration of the mucosa with_______
  • _________
  • intermittent airway narrowing (due_______
A
inflammatory cells (especially eosinophils) and cellular
elements

airway hyper-responsiveness

to bronchoconstriction, congestion or oedema of
bronchial mucosa or a combination of these)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

About 90% of children with atopic symptoms
and asthma demonstrate ________
responses to dust mite extract

A

positive skin-prick

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Classic Sx of BA

A
  • wheezing
  • coughing (especially at night)
  • tightness in the chest
  • breathlessness
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Auscultation findings of BA

A

diffuse, high-pitched wheezes throughout inspiration and most of expiration, which is usually prolonged

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

If wheeze
is not present during normal tidal breathing it may
become apparent during a ______

A

forced expiration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Spirometry: a value of________ for FEV 1 /VC ratio
indicates obstruction. It is the more accurate test
and recommended for those who can perform it
(i.e. most adults and children >6 years).

A

<75%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Measurement of peak expiratory flow rate
(PEFR) or spirometry before and after SA β A: has
a characteristic_________

A

improvement >15% in FEV 1 and

PEFR.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

__________ airway reactivity is
tested in a respiratory laboratory to inhaled
histamine, methacholine or hypertonic saline.
Sometimes useful to confirm diagnosis

A

Inhalation challenge tests:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Other tests for BA

A

Mannitol inhalation test.

An exercise challenge may also be helpful.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Significant advances in the management of asthma

The realisation that asthma is an inflammatory
disease. Therefore the appropriate first- or secondline
treatment in moderate to severe asthma
is ____ or _________

A

inhaled sodium cromoglycate (especially in

children) or inhaled corticosteroids (ICS).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Significant advances in the management of asthma

2 The regular use of _________
3 The use of spacers attached to_______
4 Improved and more efficient inhalers.
5 Combined________

A

spirometry.

inhalers/puffers.

long-acting relievers and preventers including combinations of long-acting β -agonists
(LA β A) and ICS—the fixed-dose inhalers.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Patients with moderate to severe chronic asthma
require regular measurement of ______ which is more
useful than subjective symptoms in assessing asthma
control

A

PEFR,

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Goal of measuring PEFR

A

This allows the establishment of a baseline
of the ‘patient’s best’, monitors changes, and allows
the assessment of asthma severity and response to
treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

______ are not a substitute for spirometry

A

Peak flow meters

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Some people who have trouble using metered dose
inhalers (MDIs) can have a special________fitted onto
the mouthpiece of the inhaler

A

‘spacer’

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Children under 5–6 years and/or 20 kg can use an

MDI and a ______

A

small volume valved spacer (AeroChamber,

Breath-A-Tech) with a face mask.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Goals of BA Tx

• absent or minimal _________
• maintain best possible lung function at all
times—keep asthma under control

A

daytime symptoms and no nocturnal symptoms; restore normal airway function (>80% of predicted)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Definition of good BA control
• Minimal symptoms day and night • No nocturnal waking due to asthma • No limitation of normal or physical activity • Minimal need for reliever medication • No exacerbation • Normal lung function (FEV 1 and/or PEFR >80% predicted or best) • No side effects of medication • Near or near-normal lung function (i.e. >80% predicted)
26
These medications are directed towards the underlying abnormalities—bronchial hyperreactivity and associated airway inflammation
‘Preventer’ drugs or anti-inflammatory | agents
27
Treatment with a ‘preventer’ is recommended if asthma | episodes are ______ or those who use SA β A____
>3/week | >3 times a week
28
ICS types
* beclomethasone * budesonide * ciclesonide (single daily dose) * fluticasone
29
Dose range of ICS
• 400–1600 mcg (adults); aim to keep below 500 | mcg children and 1000 mcg (adults)
30
SE of ICS ``` • oropharyngeal candidiasis, dysphonia (hoarse voice)—less risk with once daily_______ • bronchial irritation: cough • _________ (doses of 2000 mcg/daily; sometimes as low as 800 mcg) ```
ciclesonide adrenal suppression
31
Intermittent BA Status before treatment Lung function FEV1 or PEFR (% predicted)
Episodic Symptoms
32
Intermittent BA Recommended β-agonist Estimated starting daily dose range of ICS required to achieve good control
SAβA prn Regular ICS not required Add preventer if ≥3 SAβA/week
33
Mild persistent Status before treatment Lung function FEV1 or PEFR (% predicted
Symptoms >weekly, not every day Night symptoms >2 per month Symptoms regularly with exercise ≥ 80%
34
Mild persistent Recommended β-agonist Estimated starting daily dose range of ICS required to achieve good control
SAβA prn ``` <250 mcg beclomethasone <400 mcg budesonide <250 mcg fluticasone <160 mcg ciclesonide Increase dose if >2 SAβA 2–3 times daily ```
35
Moderate persistent Status before treatment Lung function FEV1 or PEFR (% predicted
Symptoms every day Night symptoms >weekly Several known triggers apart from exercise 60–80 %
36
MOd persistent Recommended β-agonist Estimated starting daily dose range of ICS required to achieve good control
LAβA + SAβA prn ``` 250–400 mcg beclomethasone 400–800 mcg budesonide 250–500 mcg fluticasone 160–320 mcg ciclesonide ```
37
Severe persistent Status before treatment Lung function FEV1 or PEFR (% predicted
Symptoms every day Wakes frequently at night with cough/ wheeze, Chest tightness on waking, Limitation of physical activity <60%
38
Severe persistent Recommended β-agonist Estimated starting daily dose range of ICS required to achieve good control
LAβA + SAβA prn ``` >400 mcg beclomethasone >800 mcg budesonide >500 mcg fluticasone >320 mcg ciclesonide ```
39
ICSs have a________ curve so it may not be necessary to prescribe above ICS doses considered high
flat dose–response
40
________ is used mainly for exacerbations. It is given with the usual inhaled corticosteroids and bronchodilators
Prednisolone
41
Dose of Prednisolone
• up to 1 mg/kg/day for 1–2 weeks
42
These are sodium cromoglycate (SCG) and nedocromil | sodium
Cromolyns
43
AE for Cromolyns
local irritation may be caused by the dry powder. Systemic | effects do not occur.
44
_______is used for frequent episodic asthma in children over 2 years of age for the prevention of exercise-induced asthma and the treatment of mildto- moderate asthma in some adults
Nedocromil
45
These drugs, which include montelukast and zafirlukast, are very useful for seasonal asthma and aspirin-sensitive asthma and reduce the need for inhaled steroids or
Leucotriene antagonists
46
Montelukast is taken as a _________
5 or 10 mg chewable tablet once daily
47
Indications for preventive therapy Guidelines for introducing preventive asthma therapy in adults and children include any of the following: * requirement of β 2 -agonist _______ * symptoms (non-exercise______ * spirometry showing ______
>3–4 times each week or >1 canister every 3 months (excluding preexercise) >3–4 times per week between attacks reversible airflow obstruction during asymptomatic phases
48
Indications for preventive therapy Guidelines for introducing preventive asthma therapy in adults and children include any of the following: • asthma significantly interfering with physical activity despite appropriate pre-treatment • asthma attacks_______ • infrequent asthma attacks but ________
>every 6–8 weeks severe or lifethreatening
49
The three groups of bronchodilators are 1 2 3
• the β 2 -adrenoceptor agonists ( β 2 -agonists)— short acting (SA β A) and long acting (LA β A) • methylxanthines—theophylline derivatives • anticholinergics
50
These drugs ‘stimulate’ the β 2 adrenoreceptors and thus relax bronchial smooth muscle. The inhaled route of delivery is the preferred route
β 2 -agonists
51
Onset of B2 agonist
The inhaled drugs produce measurable bronchodilation in 1–2 minutes and peak effects by 10–20 minutes
52
The traditional agents such as _______are short-acting preparations. The new longer acting agents (LA β A) include____
salbutamol and terbutaline salmeterol, eformoterol and vilanterol.
53
These oral drugs may have complementary value to the inhaled agents but tend to be limited by side effects and efficacy
Theophylline derivatives
54
This anti-IgE agent is marketed for SC injection in patients >12 years with moderate to severe allergic asthma treated by ICS and who have raised serum IgE levels
Omalizumab
55
This term is reserved for those medications that are taken prior to known trigger factors, particularly for exercise-induced asthma
Prophylactic agents
56
Meds of exercise induced asthma
β 2 -agonist inhaler (puffer): two puffs 5 minutes immediately before exercise last 1–2 hours. LA β A such as salmeterol and eformoterol are more effective
57
Other drugs for exercise induced asthma
• SCG or nedocromil, two puffs. • Combination β 2 -agonist + SCG (5–10 minutes beforehand). • Montelukast 10 mg (less in children ≥ 2 years) (o) daily or 1–2 hours beforehand
58
What are the 3 steps in BA control
Step 1: Assess asthma symptom control and identify the patient’s risk factors Step 2: Treat and adjust to achieve good control. Step 3: Review response and monitor to maintain control
59
For breakthrough asthma or persistent poorly controlled asthma with poor compliance switch to _________
``` combined medication (e.g. Seretide MDI Accuhaler, or Symbicort). ```
60
Techniques on how to use MDI The open-mouth technique and the closed-mouth technique are the main methods, and both are effective but the _________ is preferred
closed-mouth technique
61
The usual dose of standard MDI is _____
one or two puffs (adult) every 3–4 hours for an attack (four puffs in children
62
The _______ is a breath-activated MDI which can improve lung deposition in patients with poor inhaler technique.
Autohaler
63
The _______ is a dry powder delivery system that is widely used as an alternative to the MDI. It is a breath-activated device
Turbuhaler
64
People who have experienced one or more of the | following are more likely to have severe attacks:
• previous severe asthma attack • previous hospital admission, especially admission to intensive care • hospital attendance in the past 12 months • long-term oral steroid treatment • carelessness with taking medication • night-time attacks, especially with severe chest tightness • recent emotional problems • frequent SA β A use
65
Dangerous sign (pulse) associated with BA
Pulsus paradoxus
66
T or F This is a good sign in BA Chest becoming ‘silent’ with a quiet wheeze, yet breathing still laboured
f
67
Patients who are sensitive to________ need to be reminded that salicylates are present in common cold cure preparations and agents such as Alka-Seltzer
aspirin/salicylates
68
The non-steroidal medications, ______, ________ or _________ by inhalation, are the prophylactic drugs of choice in childhood chronic asthma of mild-to-moderate severity.
montelukast (oral) | and SCG and/or nedocromil sodium
69
ICS in children Any dose equal to or greater than _______ in children can have side effects, including growth suppression and adrenal suppression
400 mcg